Recent Articles in Industry Insights

Shanghai NovoCodex Biopharm started a China Phase 1 trial of an anti-CD70 ADC in patients with advanced solid tumors. NovoCodex, a majority owned subsidiary of Zhejiang Medicine, acquired China rights to the candidate, ARX305, from San Diego’s Ambrx in 2019, its second in-licensing from the company. According to Ambrx, ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein overexpressed in a broad range of solid and hematologic tumors. More details....

Stock Symbols: (SHA: 600216) (NYSE: AMAM)

Share this with colleagues:  

Sirnaomics reported that its lead product, an siRNA (small interfering RNA) therapy, produced a 100% complete response in patients with cutaneous basal cell carcinoma. Five patients received a 180μg dose of STP705 in the Phase II clinical trial of STP705. The candidate is composed of two siRNA oligonucleotides that target the expression of TGF-β1 and COX-2 mRNA, respectively. BCC is a nonmelanoma skin cancer associated with exposure to ultraviolet radiation from the sun. Sirnaomics is a Suzhou-Maryland biotech dedicated to RNAi drug development. More details....

Stock Symbol: (HK: 2257)

Share this with colleagues:  

Sino Biological partnered with California’s Ainnocence to add the company’s AI-based prediction technology to its antibody development CRO services. Ainnocence said its platform provides fast, efficient and accurate prediction of antibody-antigen interaction, including binding affinity assessment. The third-generation AI system delivers virtual screening and multi-objective pharmacological profile optimization for small molecule, antibody and other complex therapies. Sino Bio is a global reagent supplier that also offers CRO services. Terms of the agreement were not disclosed. More details....

Stock Symbol: (SHA: 301047)

Share this with colleagues: